Cloudbreak Pharma Inc. (2592.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$1.19 (+2.15%) as of
Key statistics
- Market cap
- 1.10B
- EPS (TTM)
- -1.150
- Dividend yield
- 0.00%
- 52-week range
- 0.900 – 9.580
- Revenue (TTM)
- 269k
- Profit margin
- 0.00%
- Volume
- 18.50k
About Cloudbreak Pharma Inc.
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingredient of hydroxypropyl beta-cyclodextrins that is in Phase 2 clinical trial for the treatment of meibomian gland dysfunction associated dry eye disease. It also develops CBT-199 and CBT-145 for the treatment of presbyopia, a condition caused by an age-related process; CBT-007, an eye drop for enhancing success rate of glaucoma filtration surgery; and CBT-011, an antibody-drug-synergism conjugate for the treatment of diabetic macular edema. The company was founded in 2015 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Irvine, CA, United States
- Employees
- 61
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.